Vericiguat is a Small Molecule owned by Bayer, and is involved in 42 clinical trials, of which 35 were completed, 3 are ongoing, and 4 are planned.

Vericiguat acts as a soluble guanylyl cyclase (sGC) stimulator. Soluble guanylate cyclase (sGC) is a key enzyme of the nitric oxide (NO) signaling pathway. On binding of NO to a prosthetic heme group on sGC, the enzyme catalyzes synthesis of the second messenger cGMP, which produces vasorelaxation and inhibits smooth muscle proliferation, leukocyte recruitment, and platelet aggregation through a number of downstream mechanisms. It regulates several important physiological processes by converting GTP into the second-messenger cGMP.

The revenue for Vericiguat is expected to reach a total of $5.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Vericiguat NPV Report.

Vericiguat is originated and owned by Bayer. Merck & Co is the other company associated in development or marketing of Vericiguat.

Vericiguat Overview

Vericiguat (Verquvo) is a pyrazolopyridine derivative, acts as a vasodilator agent and an antihypertensive agent. It is formulateda as film-coated tablets for oral route of administration. Verquvo is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%. Vericiguat (BAY-1021189) is under development for the treatment of chronic heart failure with reduced ejection fraction (HFpEF). The drug candidate is administered orally. It targets soluble guanylyl cyclase (sGC). It was also under development for the treatment of heart failure with preserved ejection fraction (HFpEF) and coronary artery disease,

Bayer Overview

Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.

The company reported revenues of (Euro) EUR44,081 million for the fiscal year ended December 2021 (FY2021), an increase of 6.5% over FY2020. The operating profit of the company was EUR3,353 million in FY2021, compared to an operating loss of EUR16,169 million in FY2020. The net profit of the company was EUR1,000 million in FY2021, compared to a net loss of EUR10,495 million in FY2020. The company reported revenues of EUR11,281 million for the third quarter ended September 2022, a decrease of 12% over the previous quarter.

Quick View – Vericiguat

Report Segments
  • Innovator (NME)
Drug Name
  • Vericiguat
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.